Sanofi Cash Flow from Investing Activities 2010-2025 | SNY
Sanofi annual/quarterly cash flow from investing activities history and growth rate from 2010 to 2025. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- Sanofi cash flow from investing activities for the quarter ending March 31, 2025 was $-0.818B, a 0% increase year-over-year.
- Sanofi cash flow from investing activities for the twelve months ending March 31, 2025 was $-9.262B, a 7.94% decline year-over-year.
- Sanofi annual cash flow from investing activities for 2024 was $-4.769B, a 28.93% decline from 2023.
- Sanofi annual cash flow from investing activities for 2023 was $-6.71B, a 206.93% increase from 2022.
- Sanofi annual cash flow from investing activities for 2022 was $-2.186B, a 74.68% decline from 2021.
Sanofi Annual Cash Flow Investing
(Millions of US $) |
| 2024 |
$-4,769 |
| 2023 |
$-6,710 |
| 2022 |
$-2,186 |
| 2021 |
$-8,634 |
| 2020 |
$4,099 |
| 2019 |
$-1,357 |
| 2018 |
$-15,195 |
| 2017 |
$-3,273 |
| 2016 |
$-2,779 |
| 2015 |
$-3,343 |
| 2014 |
$-4,599 |
| 2013 |
$-1,691 |
| 2012 |
$-2,041 |
| 2011 |
$-20,476 |
| 2010 |
$-4,492 |
| 2009 |
$-10,162 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$132.073B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
